Justin A Ezekowitz

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3700036/justin-a-ezekowitz-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 21,880 336 143 h-index g-index citations papers 28,624 6.71 6.5 370 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
336	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association	12.3	50
335	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users <i>CJC Open</i> , 2022 , 4, 180-188	2	
334	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008970	7.6	O
333	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial <i>Lancet, The</i> , 2022 , 399, 1391-1400	40	2
332	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis <i>Journal of the American Heart Association</i> , 2022 , 11, e024833	6	O
331	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e021094	6	2
330	The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. <i>ESC Heart Failure</i> , 2021 ,	3.7	1
329	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. <i>The Lancet Digital Health</i> , 2021 ,	14.4	8
328	Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. <i>Contemporary Clinical Trials</i> , 2021 , 113, 106646	2.3	O
327	Chloride in Heart Failure: The Neglected Electrolyte. <i>JACC: Heart Failure</i> , 2021 , 9, 904-915	7.9	3
326	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2021 ,	14.6	2
325	Evidence-Based Management of Acute Heart Failure. Canadian Journal of Cardiology, 2021, 37, 621-631	3.8	5
324	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 531-546	3.8	48
323	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. <i>Journal of Cardiac Failure</i> , 2021 , 27, 602-606	3.3	2
322	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e019712	6	1
321	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021 , 14, e008100	7.6	4
320	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 336-345	7.9	6

(2021-2021)

319	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021 , 143, 2129-2142	16.7	14
318	Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials. <i>Current Cardiovascular Risk Reports</i> , 2021 , 15, 13	0.9	1
317	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 497-505	7.9	1
316	Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2021 , 22, 220-228	4.1	4
315	Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. <i>CJC Open</i> , 2021 , 3, 361-366	2	0
314	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , 27, 297-308	3.3	2
313	Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	6
312	Cost-Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation. <i>Journal of the American Heart Association</i> , 2021 , 10, e019599	6	1
311	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1488-1498	12.3	7
310	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2021 , 174, 1065-1072	8	6
309	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021 , 144, 1489-1499	16.7	5
308	Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. <i>Circulation: Heart Failure</i> , 2021 , 14, e008242	7.6	2
307	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	9.5	875
306	Impact of Atrial Fibrillation Case Volume in the Emergency Department on Early and Late Outcomes of Patients With New Atrial Fibrillation. <i>Annals of Emergency Medicine</i> , 2021 , 78, 242-252	2.1	O
305	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021 , 18, 253-263	2.8	1
304	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021 , 154, 123	- 1 26	1
303	Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. <i>Journal of Cardiac Failure</i> , 2021 , 27, 934-941	3.3	
302	Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Failure, 2021	3.7	2

301	The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	1
300	Real world Data on the Concurrent Use of P-glycoprotein or Cytochrome 3A4 Drugs and Non-vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation. <i>European Heart Journal Quality of Care & Dinical Outcomes</i> , 2021 ,	4.6	1
299	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020 , 9, e0124	105	2
298	Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population. <i>Circulation: Heart Failure</i> , 2020 , 13, e006952	7.6	1
297	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1148-1151	3.8	11
296	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	9.5	42
295	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020 , 227, 56-63	4.9	6
294	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020 , 41, 1357-1364	9.5	20
293	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020 , 2, 151-16	50 ²	4
292	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial '- însights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 1022-1031	12.3	11
291	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020 , 382, 1883-1893	59.2	333
2 90	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 2725-2733	3.7	4
289	Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. <i>International Journal of Cardiology</i> , 2020 , 317, 167-173	3.2	8
288	Underrepresentation of Women in Cardiovascular Randomized Clinical Trials. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 969.e7-969.e8	3.8	4
287	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020 , 13, 540-548	3.3	2
286	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 159-1	6 ³ 9 ⁸	50
285	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020 , 5, 757-764	16.2	26
284	Elevated Blood Pressure and Associations with Sodium Intake Among Multiethnic Youth in Edmonton, Canada: Findings from WHY ACT NOW. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 239-249	2.9	1

283	The Effect of Carotid Chemoreceptor Inhibition on Exercise Tolerance in Chronic Heart Failure. <i>Frontiers in Physiology</i> , 2020 , 11, 195	4.6	1
282	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020,	6.4	2
281	OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B). <i>Circulation</i> , 2020 , 141, 818-827	16.7	11
280	Design and Region-Specific Adaptation of the Dietary Intervention Used in the SODIUM-HF Trial: A Multicentre Study. <i>CJC Open</i> , 2020 , 2, 8-14	2	3
279	Impact of cardiology follow-up care on treatment and outcomes of patients with new atrial fibrillation discharged from the emergency department. <i>Europace</i> , 2020 , 22, 695-703	3.9	9
278	Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 274-278	3.7	3
277	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. <i>JACC: Heart Failure</i> , 2020 , 8, 931-939	7.9	30
276	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1512-1521	27.4	71
275	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020 , 142, 2231-2239	16.7	15
274	Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020 , 22, 81	6.9	7
273	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13625	2.9	2
272	Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020 , 9, e017278	6	5
271	Ambulance use, distance and outcomes in patients with suspected cardiovascular disease: a registry-based geographic information system study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 45-58	4.3	9
270	Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 103-110	2.1	1
269	Management of Comorbidities in Heart Failure 2020 , 687-696.e2		
268	Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades. <i>JAMA Cardiology</i> , 2019 , 4, 1122-1128	16.2	19
267	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1205-1217	15.1	28
266	Quantification of lung water in heart failure using cardiovascular magnetic resonance îmaging. Journal of Cardiovascular Magnetic Resonance, 2019 , 21, 58	6.9	5

265	A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart Function Clinics. <i>CJC Open</i> , 2019 , 1, 173-181	2	О	
264	Empirical Insights When Defining the Population Burden of Atrial Fibrillation and Oral Anticoagulation Utilization Using Administrative Data. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1412-1	43.8	4	
263	The Relationship Between Heart-Failure Hospitalization and Mortality in Patients Receiving Transcatheter Aortic Valve Replacement. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 413-421	3.8	3	
262	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019 , 12, e005998	7.6	22	
261	External Validation and Refinement of Emergency Heart Failure Mortality Risk Grade Risk Model in Patients With Heart Failure in the Emergency Department. <i>CJC Open</i> , 2019 , 1, 123-130	2	5	
260	External Validation of the HF-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2019 , 139, 2377-2379	16.7	21	
259	High vs. low oxygen therapy in patients with acute heart failure: HiLo-HF pilot trial. <i>ESC Heart Failure</i> , 2019 , 6, 667-677	3.7	9	
258	Incremental costs of high intensive care utilisation in patients hospitalised with heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 660-666	4.3	3	
257	Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. <i>European Heart Journal</i> , 2019 , 40, 2110-2117	9.5	29	
256	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019 , 21, 770-778	12.3	13	
255	Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 710-718	5.8	7	
254	The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	75	
253	Update on the diagnosis and management of acute heart failure. <i>Current Opinion in Cardiology</i> , 2019 , 34, 202-206	2.1	5	
252	2017 Guidelines for the management of heart failure by pharmacists. <i>Canadian Pharmacists Journal</i> , 2019 , 152, 301-316	1.3	O	
251	Screening and Initiating Supportive Care in Patients With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 151	5.4	3	
250	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2511-2524	15.1	32	
249	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019 , 139, 2292-2300	16.7	47	
248	Heart failure treatment and the art of medical decision making. European Journal of Heart Failure, 2019 , 21, 1510-1514	12.3	3	

247	Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. Journal of Cardiovascular Pharmacology, 2019 , 73, 149-154	3.1	11
246	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019 , 7, 158-168	7.9	26
245	Frailty modelling for multitype recurrent events in clinical trials. Statistical Modelling, 2019, 19, 140-156	5 0.7	1
244	Insights on the Use of Twitter at the Canadian Cardiovascular Congress. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 813.e7-813.e8	3.8	3
243	Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).	6	7
242	Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010-2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	13
241	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018 , 20, 525-532	12.3	21
240	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 298-307	7.9	2
239	Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. <i>Heart</i> , 2018 , 104, 1691-1698	5.1	25
238	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. <i>ESC Heart Failure</i> , 2018 , 5, 19-26	3.7	7
237	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 96-104	7.9	83
236	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018 , 107, 170-181	6.1	22
235	Prediction of Early Adverse Events in Emergency Department Patients With Acute Heart Failure: A Systematic Review. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 168-179	3.8	10
234	Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF). <i>American Heart Journal</i> , 2018 , 205, 87-96	4.9	6
233	Reply to McClure et alReader Commentary on 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 813.e3	3.8	
232	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018 , 122, 1506-1512	3	11
231	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 1666-1676	16.7	23
230	Effects of age, gender, and risk-factors for heart failure on native myocardial T and extracellular volume fraction using the SASHA sequence at 1.5T. <i>Journal of Magnetic Resonance Imaging</i> , 2018 , 48, 1307-1317	5.6	8

229	The high cost of critical care unit over-utilization for patients with NSTE ACS. <i>American Heart Journal</i> , 2018 , 202, 84-88	4.9	14
228	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018 , 20, 304-314	12.3	30
227	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. <i>Open Heart</i> , 2018 , 5, e000908	3	4
226	Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. Journal of the American College of Cardiology, 2018 , 72, 2551-2562	15.1	13
225	Acute Coronary Syndromes and Heart Failure Critical Care Units Utilization and Outcomes in Teaching and Community Hospitals: A National Population-Based Analysis. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1365-1368	3.8	1
224	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004783	5.8	7
223	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. <i>Cmaj</i> , 2018 , 190, E1192-E1206	3.5	16
222	Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. <i>Echocardiography</i> , 2018 , 35, 1746-1754	1.5	7
221	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018 , 41, 945-952	3.3	11
220	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2018 , 11, e004646	7.6	81
219	Examining the Influence of Component Outcomes on the Composite at the Design Stage. Circulation: Cardiovascular Quality and Outcomes, 2018 , 11, e004419	5.8	1
218	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 1031-1038	12.3	18
217	Influence of hospital volume on outcomes for patients with heart failure: Evidence from a Canadian national cohort study. <i>American Heart Journal</i> , 2018 , 202, 148-150	4.9	11
216	Composite End Points in Clinical Trials of Heart Failure Therapy: How Do We Measure the Effect Size?. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	13
215	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 166-169	3.8	10
214	Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 911-917	3.8	8
213	Identifying Low-risk Patients for Early Discharge From Emergency Department Without Using Subjective Descriptions of Chest Pain: Insights From Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) 3 and 4 Trials. <i>Academic Emergency Medicine</i> , 2017 , 24, 691-700	3.4	1
212	Letter by Brown and Ezekowitz Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective". <i>Circulation</i> , 2017 , 135, e889-e891	16.7	3

(2017-2017)

Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. <i>American Heart Journal</i> , 2017 , 188, 127-135	4.9	5
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017 , 38, 2364-2373	9.5	72
Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. <i>JACC: Heart Failure</i> , 2017 , 5, 388-392	7.9	5
Multitype Events and the Analysis of Heart Failure Readmissions: Illustration of a New Modeling Approach and Comparison With Familiar Composite End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	2
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 3029-3039	15.1	41
Dietary Self-management in Heart Failure: High Tech or High Touch?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017 , 19, 19	2.1	4
2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 712-744	15.1	18
Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 1-13	7.9	58
2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10, e000022	5.8	6
The Impact and Implications of Twitter for Cardiovascular Medicine. <i>Journal of Cardiac Failure</i> , 2017 , 23, 266-267	3.3	9
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology, 2017 , 35, 870-877	2.2	207
Subclinical Pulmonary Edema Is Associated With Reduced Exercise Capacity in HFpEF and HFrEF. Journal of the American College of Cardiology, 2017 , 70, 1827-1828	15.1	9
Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 2017, 318, 713-720	27.4	236
Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	14
Letter by Kaul et al Regarding Article, "Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012". <i>Circulation</i> , 2017 , 136, 884-885	16.7	
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1342-1433	3.8	330
Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1472-1477	3.8	17
Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. <i>ESC Heart Failure</i> , 2017 , 4, 301-311	3.7	24
	unit admission: Derivation, validation, and refinement of a risk score. <i>American Heart Journal</i> , 2017, 188, 127-135 Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373 Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. <i>JACC: Heart Failure</i> , 2017, 5, 388-392 Multitype Events and the Analysis of Heart Failure Readmissions: Illustration of a New Modeling Approach and Comparison With Familiar Composite End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039 Dietary Self-management in Heart Failure: High Tech or High Touch?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 19 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2017, 69, 712-744 Body Weight Change During and After Hospitalization for Acute Heart Failure; Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. <i>JACC: Heart Failure</i> , 2017, 5, 1-13 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, e000022 The Impact and Implications of Twitter for Cardiovascular Medicine. <i>Journal of Cardiac Pailure</i> , 2017, 23, 266-267 Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 1014-Breast): A Ra	unit admission: Derivation, validation, and refinement of a risk score. American Heart Journal, 2017, 188, 127-135 Blased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). European Heart Journal, 2017, 38, 246-2373 Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392 Multitype Events and the Analysis of Heart Failure Readmissions: Illustration of a New Modeling Approach and Comparison With Familiar Composite End Points. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. Journal of the American College of Cardiology, 2017, 69, 3029-3039 Dietary Self-management in Heart Failure: High Tech or High Touch?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 19 2016 AHA/ACC Clinical Performance and Quality Measures For Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Journal of the American College of Cardiology, 2017, 69, 712-744 Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. JACC: Heart Failure, 2017, 5, 1-13 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Medicine. Journal of Cardiac Failure, 2017, 23, 26-6-267 Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology, 2017, 35,

193	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 1310-1320	12.3	39
192	Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2017 , 2, 86-87	16.2	1
191	Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria. <i>International Journal of Cardiology</i> , 2017 , 228, 558-562	3.2	20
190	Power and Sample Size Estimation for Nonparametric Composite Endpoints: Practical Implementation using Data Simulations. <i>Journal of Modern Applied Statistical Methods</i> , 2017 , 16, 215-23	6 ^{0.3}	2
189	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 296-310	3.8	65
188	Early Follow-Up After a Heart Failure Exacerbation: The Importance of Continuity. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	31
187	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiology, 2016 , 1, 673-81	16.2	59
186	Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>BMJ Open</i> , 2016 , 6, e010201	3	8
185	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016 , 117, 1771-8	3	23
184	Factors Associated With Natriuretic Peptide Testing in Patients Presenting to Emergency Departments With Suspected Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 986.e1-8	3.8	5
183	Oxygen Therapy in Patients With Acute Heart Failure: Friend or Foe?. JACC: Heart Failure, 2016, 4, 783-7	9,0 9	42
182	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016 , 13, 140-8	2.2	12
181	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016 , 117, 404-11	3	38
180	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1444-1455	15.1	142
179	Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. <i>Circulation: Heart Failure</i> , 2016 , 9, e002639	7.6	77
178	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016 , 22, 409-16	3.3	3
177	Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?. <i>American Heart Journal</i> , 2016 , 175, 184-92	4.9	20
176	Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1356.e21-1356.e28	3.8	9

175	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1038.e5-9	3.8	8
174	Cognitive decline in heart failure. <i>Heart Failure Reviews</i> , 2016 , 21, 661-673	5	44
173	Salt in the diet in patients with heart failure: what to recommend. <i>Current Opinion in Cardiology</i> , 2016 , 31, 196-203	2.1	10
172	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016 , 18, 306-13	12.3	26
171	Insights into the importance of the electrocardiogram in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016 , 18, 1032-40	12.3	13
170	Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada. <i>American Journal of Cardiovascular Drugs</i> , 2016 , 16, 365-76	4	4
169	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016 , 18, 424-32	12.3	28
168	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016 , 18, 684-92	12.3	12
167	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 388, 2895-2903	40	158
166	The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. <i>CMAJ Open</i> , 2016 , 4, E365-E370	2.5	52
165	Gull ESC 2016 sobre el diagnilitico y tratamiento de la insuficiencia cardiaca aguda y crilica. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 1167.e1-1167.e85	1.5	91
164	Changes in dietary intake and nutritional status associated with a significant reduction in sodium intake in patients with heart failure. A sub-analysis of the SODIUM-HF pilot study. <i>Clinical Nutrition ESPEN</i> , 2016 , 11, e26-e32	1.3	19
163	The Nobesity paradoxNn atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. <i>European Heart Journal</i> , 2016 , 37, 2869-2878	9.5	144
162	Letter by McAlister and Ezekowitz Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings From Get With the Guidelines-Heart Failure". <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	
161	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	10
160	The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015 , 169, 743-50	4.9	14
159	Reply: Coenzyme q10: will this natural substance become a guideline-directed adjunctive therapy in heart failure?. <i>JACC: Heart Failure</i> , 2015 , 3, 271-2	7.9	
158	Assessing the use of international classification of diseases-10th revision codes from the emergency department for the identification of acute heart failure. <i>JACC: Heart Failure</i> , 2015 , 3, 386-39	7 .9	25

157	Diuretic response in acute heart failure-an analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015 , 170, 313-21	4.9	76
156	Association between self-reported adherence to a low-sodium diet and dietary habits related to sodium intake in heart failure patients. <i>Journal of Cardiovascular Nursing</i> , 2015 , 30, 58-65	2.1	19
155	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015 , 170, 290-7	4.9	41
154	Estimates of Dietary Sodium Consumption in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2015 , 21, 981-8	3.3	15
153	Heart failure guidelines fail. <i>Cmaj</i> , 2015 , 187, 912	3.5	
152	Re. "Dietary fatty acids intake and mortality in patients with heart failure": AuthorsNesponse. <i>Nutrition</i> , 2015 , 31, 1185-6	4.8	
151	The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study. <i>American Heart Journal</i> , 2015 , 169, 274-281.e1	4.9	39
150	Early management of patients with acute heart failure: state of the art and future directionsa consensus document from the SAEM/HFSA acute heart failure working group. <i>Academic Emergency Medicine</i> , 2015 , 22, 94-112	3.4	30
149	Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. <i>Journal of Cardiac Failure</i> , 2015 , 21, 27-43	3.3	55
148	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 86-94	6.4	44
147	How to Do More With Less. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 460-2	5.8	2
146	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). <i>Journal of the American Heart Association</i> , 2015 , 4,	6	21
145	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015 , 17, 1182-91	12.3	37
144	The Prognostic Importance of Changes in Renal Function during Treatment for Acute Heart Failure Depends on Admission Renal Function. <i>PLoS ONE</i> , 2015 , 10, e0138579	3.7	11
143	Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study. <i>PLoS ONE</i> , 2015 , 10, e0140607	3.7	7
142	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015 , 170, 298-305	4.9	32
141	Variation in critical care unit admission rates and outcomes for patients with acute coronary syndromes or heart failure among high- and low-volume cardiac hospitals. <i>Journal of the American Heart Association</i> , 2015 , 4, e001708	6	29
140	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. <i>Journal of the American Heart Association</i> 2015, 4, e002092	6	19

139	The Effects of Climate Change on Cardiac Health. Cardiology, 2015, 131, 209-17	1.6	37
138	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 3-16	3.8	77
137	Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. <i>American Heart Journal</i> , 2015 , 169, 122-31.e2	2 4.9	20
136	Peripheral chemoreceptor control of cardiovascular function at rest and during exercise in heart failure patients. <i>Journal of Applied Physiology</i> , 2015 , 118, 839-48	3.7	13
135	Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 193-201	7.9	62
134	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2015 , 17, 340-6	12.3	13
133	Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. <i>International Journal of Cardiology</i> , 2015 , 182, 184-6	3.2	1
132	Metabolomic fingerprint of heart failure with preserved ejection fraction. <i>PLoS ONE</i> , 2015 , 10, e012484	4 3.7	106
131	Risk stratification in acute heart failure. Canadian Journal of Cardiology, 2014, 30, 312-9	3.8	31
130	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 249-63	3.8	36
129	Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014 , 177, 840-6	3.2	9
128	Rates and reasons for device-based guideline eligibility in patients with heart failure. <i>Heart Rhythm</i> , 2014 , 11, 1983-90	6.7	8
127	Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. <i>JACC: Heart Failure</i> , 2014 , 2, 457-65	7.9	84
126	Trends in death attributed to myocardial infarction, heart failure and pulmonary embolism in Europe and Canada over the last decade. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014 , 107, 813-20	2.7	19
125	Dietary fatty acids intake and mortality in patients with heart failure. <i>Nutrition</i> , 2014 , 30, 1366-71	4.8	18
124	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1208-15	3.8	10
123	Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?. <i>American Heart Journal</i> , 2014 , 168, 60-7.e5	4.9	16
122	Mortality outcomes among status Aboriginals and whites with heart failure. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 619-26	3.8	6

121	Heart failure re-admission: measuring the ever shortening gap between repeat heart failure hospitalizations. <i>PLoS ONE</i> , 2014 , 9, e106494	3.7	23
120	Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. <i>Circulation: Heart Failure</i> , 2014 , 7, 918-25	7.6	37
119	Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). <i>Circulation</i> , 2014 , 130, 958-65	16.7	36
118	The association between meteorological events and acute heart failure: new insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014 , 177, 819-24	3.2	9
117	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 334-41	12.3	41
116	Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2014 , 14, 133	2.3	18
115	Representativeness of RELAX-AHF clinical trial population in acute heart failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 259-68	5.8	29
114	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. <i>BMC Cardiovascular Disorders</i> , 2014 , 14, 91	2.3	22
113	High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , 2014 , 20, 319-26	3.3	37
112	Determinants of early readmission after hospitalization for heart failure. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 612-8	3.8	31
111	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014 , 167, 267-273.e1	4.9	9
110	Optimizing Therapy of Heart Failure in the Aging Population with Monitoring in Clinics 2014 , 85-93		
109	Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data. <i>International Journal of Biometeorology</i> , 2013 , 57, 401-8	3.7	4
108	Novel pharmacologic therapies in development for acute decompensated heart failure. <i>Current Cardiology Reports</i> , 2013 , 15, 329	4.2	4
107	Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1177-83	15.1	61
106	Similarities and differences in patient characteristics between heart failure registries versus clinical trials. <i>Current Heart Failure Reports</i> , 2013 , 10, 373-9	2.8	12
105	Myocardial deformation analysis in contrast echocardiography: first results using two-dimensional cardiac performance analysis. <i>Journal of the American Society of Echocardiography</i> , 2013 , 26, 1282-9	5.8	6
104	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013 , 15, 456-64	12.3	32

103	Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>Circulation: Heart Failure</i> , 2013 , 6, 45	1-66	106
102	The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 168-81	3.8	157
101	Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013 , 1, 523-30	7.9	19
100	Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 423-	8 ^{3.8}	7
99	The relationship between meteorological conditions and index acute coronary events in a global clinical trial. <i>International Journal of Cardiology</i> , 2013 , 168, 2315-21	3.2	11
98	Incidence of heart failure and mortality after acute coronary syndromes. <i>American Heart Journal</i> , 2013 , 165, 379-85.e2	4.9	53
97	Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. <i>International Journal of Cardiology</i> , 2013 , 168, 2127-33	3.2	30
96	Acute decompensated heart failure: update on new and emerging evidence and directions for future research. <i>Journal of Cardiac Failure</i> , 2013 , 19, 371-89	3.3	49
95	N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2274-84	15.1	149
94	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013 , 34, 2464-71	9.5	127
93	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program. <i>Circulation: Heart Failure</i> , 2013 , 6, 1132-8	7.6	26
92	Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Circulation: Cardiovascular Quality and Outcomes,	5.8	21
91	The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. <i>Critical Care Medicine</i> , 2013 , 41, 2080-7	1.4	27
90	Changes in heart failure outcomes after a province-wide change in health service provision a natural experiment in Alberta, Canada. <i>Circulation: Heart Failure</i> , 2013 , 6, 76-82	7.6	24
89	Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. <i>Circulation: Heart Failure</i> , 2013 , 6, 727-32	7.6	85
88	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure. <i>Cmaj</i> , 2013 , 185, E681-9	3.5	67
87	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 435-8	6.1	О
86	Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). <i>Trials</i> , 2013 , 14, 332	2.8	4

85	Effect of low-dose dopamine on cardio-respiratory physiology in heart failure patients. <i>FASEB Journal</i> , 2013 , 27, 928.6	0.9	
84	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1749-58	40	150
83	Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012 , 18, 94-106	3.3	78
82	Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012 , 18, 265-81	3.3	42
81	Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. <i>American Heart Journal</i> , 2012 , 164, 365-72	4.9	118
80	Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1441-8	15.1	29
79	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012 , 59, E1029	15.1	3
78	Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 106-13	5.1	20
77	The timing of implantable cardioverter-defibrillator implantation in patients with heart failure. <i>Current Cardiology Reports</i> , 2012 , 14, 299-307	4.2	1
76	Acute heart failure: perspectives from a randomized trial and a simultaneous registry. <i>Circulation: Heart Failure</i> , 2012 , 5, 735-41	7.6	19
75	Testosterone supplementation in heart failure: a meta-analysis. Circulation: Heart Failure, 2012, 5, 315-2	27 .6	138
74	Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. <i>Circulation: Heart Failure</i> , 2012 , 5, 309-14	7.6	112
73	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012 , 33, 1750-7	9.5	508
7 ²	Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1179-86	5.6	38
71	Effect of nesiritide in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , 2011 , 365, 32-43	59.2	930
70	The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. <i>American Heart Journal</i> , 2011 , 161, 986-992.e1	4.9	29
69	The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 319-38	3.8	123
68	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856

(2010-2011)

67	Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. <i>Annals of Internal Medicine</i> , 2011 , 154, 401-12	8	84
66	Carotid chemoreceptor modulation of blood flow during exercise in healthy humans. <i>Journal of Physiology</i> , 2011 , 589, 6219-30	3.9	42
65	Do anthropometric indices accurately reflect directly measured body composition in men and women with chronic heart failure?. <i>Congestive Heart Failure</i> , 2011 , 17, 90-2		19
64	The correlation of standard heart failure assessment and palliative care questionnaires in a multidisciplinary heart failure clinic. <i>Journal of Pain and Symptom Management</i> , 2011 , 42, 379-87	4.8	28
63	Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer, 2011,	4.8	68
62	Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?. European Journal of Heart Failure, 2011 , 13, 142-7	12.3	100
61	Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. <i>European Journal of Heart Failure</i> , 2011 , 13, 1211-5	12.3	6
60	Risk stratification schemes, anticoagulation use and outcomes: the risktreatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. <i>Heart</i> , 2011 , 97, 2046-50	5.1	62
59	The unrecognized burden of osteoporosis-related vertebral fractures in patients with heart failure. <i>Circulation: Heart Failure</i> , 2011 , 4, 419-24	7.6	29
58	Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. <i>Evidence-Based Medicine</i> , 2011 , 16, 138-9		
57	Ethnic differences in 1-year mortality among patients hospitalised with heart failure. <i>Heart</i> , 2011 , 97, 1048-53	5.1	19
56	Patterns of care and outcomes differ for urban versus rural patients with newly diagnosed heart failure, even in a universal healthcare system. <i>Circulation: Heart Failure</i> , 2011 , 4, 317-23	7.6	72
55	Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. <i>Circulation</i> , 2011 , 124, 289-96	16.7	137
54	Resource use in the last 6 months of life among patients with heart failure in Canada. <i>Archives of Internal Medicine</i> , 2011 , 171, 211-7		53
53	The prevalence of natural health product use in patients with acute cardiovascular disease. <i>PLoS ONE</i> , 2011 , 6, e19623	3.7	15
52	Association between obesity and health-related quality of life in patients with coronary artery disease. <i>International Journal of Obesity</i> , 2010 , 34, 1434-41	5.5	32
51	A new pathway? Failure, fragility and fractures. European Heart Journal, 2010, 31, 9-11	9.5	9
50	Association between direct measures of body composition and prognostic factors in chronic heart failure. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 609-17	6.4	111

49	Testosterone therapy in women with heart failure "why canN a woman be more like a man?". Journal of the American College of Cardiology, 2010 , 56, 1317-9	15.1	7
48	HFSA 2010 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2010 , 16, e1-194	3.3	929
47	Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2010 , 16, 475-539	3.3	231
46	Comparison of direct body composition assessment methods in patients with chronic heart failure. Journal of Cardiac Failure, 2010 , 16, 867-72	3.3	23
45	Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous	4.9	17
44	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal, 2010, 160, 272-8	4.9	26
43	Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. <i>American Heart Journal</i> , 2010 , 160, 671-7	4.9	15
42	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. <i>Canadian Journal of Cardiology</i> , 2010 ,	3.8	105
41	Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. <i>Critical Care Medicine</i> , 2010 ,	1.4	13
40	38, 1793-801 The epidemiology and management of elderly patients with myocardial infarction or heart failure. Heart Failure Reviews, 2010 , 15, 407-13	5	8
39	Management of Comorbidity in Chronic Heart Failure 2010 , 137-156		
38	A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. <i>Case Reports in Medicine</i> , 2009 , 2009, 183125	0.7	15
37	A call to action: cardiac palliative care. <i>Journal of Palliative Medicine</i> , 2009 , 12, 289-90	2.2	1
36	What price to pay? The cost of everything and the value of nothing. <i>Circulation</i> , 2009 , 119, 368-70	16.7	2
35	Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. <i>European Heart Journal</i> , 2009 , 30, 2213-9	9.5	4
34	The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. <i>European Heart Journal</i> , 2009 , 30, 2584-92	9.5	98
33	Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009 , 157, 219-28	4.9	27
32	Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 13-20	15.1	233

(2005-2009)

31	Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. <i>Annals of Internal Medicine</i> , 2009 , 150, 784-94	8	322
30	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 85-105	3.8	64
29	ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. <i>Annals of Internal Medicine</i> , 2009 , 150, JC5-10	8	2
28	Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. <i>European Heart Journal</i> , 2009 , 30, 469-77	9.5	118
27	Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction . <i>American Journal of Cardiology</i> , 2008 , 102, 79-83	3	19
26	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 21-40	3.8	78
25	Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. <i>Circulation</i> , 2008 , 118, 1946-52	16.7	110
24	Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. <i>European Journal of Heart Failure</i> , 2008 , 10, 308-14	12.3	91
23	Anemia in patients with advanced heart failure. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2301; author reply 2302	15.1	13
22	Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 2502-14	27.4	416
22		27.4	416 9
	systematic review. JAMA - Journal of the American Medical Association, 2007, 297, 2502-14 Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?. Canadian Journal of Physiology and Pharmacology,		
21	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007 , 85, 173-8 Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic	2.4	9
21	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007 , 85, 173-8 Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. <i>Annals of Internal Medicine</i> , 2007 , 147, 251-62 Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. <i>American</i>	2.4	9
21 20 19	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007 , 85, 173-8 Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. <i>Annals of Internal Medicine</i> , 2007 , 147, 251-62 Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. <i>American Journal of Cardiology</i> , 2006 , 97, 882-5 N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation	2.4	9 124 17
21 20 19	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?. Canadian Journal of Physiology and Pharmacology, 2007, 85, 173-8 Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Annals of Internal Medicine, 2007, 147, 251-62 Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. American Journal of Cardiology, 2006, 97, 882-5 N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Canadian Journal of Cardiology, 2006, 22, 393-7 Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ, The, 2005,	2.4 8 3 3.8	9 124 17 22
21 20 19 18	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007 , 85, 173-8 Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. <i>Annals of Internal Medicine</i> , 2007 , 147, 251-62 Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. <i>American Journal of Cardiology</i> , 2006 , 97, 882-5 N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 393-7 Angiotensin receptor blockers and risk of myocardial infarction: systematic review. <i>BMJ</i> , <i>The</i> , 2005 , 331, 873 Challenges in systematic reviews of therapeutic devices and procedures. <i>Annals of Internal Medicine</i>	2.4 8 3 3.8 5.9	9 124 17 22 53

13	The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 165-71	3.8	18
12	The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. <i>Archives of Internal Medicine</i> , 2004 , 164, 769-74		39
11	Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. <i>Circulation</i> , 2004 , 109, 1004-9	16.7	558
10	Usefulness of spironolactone in a specialized heart failure clinic. <i>American Journal of Cardiology</i> , 2004 , 94, 443-7	3	26
9	The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1587-	·9 ¹ 2 ^{5.1}	269
8	Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure. <i>Journal of Cardiac Failure</i> , 2004 , 10, 165-73	3.3	18
7	Systematic review: cardiac resynchronization in patients with symptomatic heart failure. <i>Annals of Internal Medicine</i> , 2004 , 141, 381-90	8	220
6	Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. <i>Circulation</i> , 2003 , 107, 223-5	16.7	657
5	Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. <i>Annals of Internal Medicine</i> , 2003 , 138, 445-52	8	180
4	Stroke: strategies for primary prevention. <i>American Family Physician</i> , 2003 , 68, 2379-86	1.3	13
3	The waiting game: facing the consequences. <i>Cmaj</i> , 2002 , 167, 1247-8	3.5	
2	Successful cryopreservation of rat islets using ethylene glycol. <i>Transplantation Proceedings</i> , 1997 , 29, 1983	1.1	3
1	Cryopreservation of rat pancreatic islets: effect of ethylene glycol on islet function and cellular composition. <i>Transplantation</i> , 1997 , 64, 1065-70	1.8	19